Refine by
Oncology Development Equipment & Supplies
5 equipment items found
Manufactured by:Eupraxia Pharmaceuticals based inVictoria, BRITISH COLUMBIA (CANADA)
Our patented technology is designed to be tailored to a wide variety of drugs and therapeutic indications. In addition to our lead drug candidate (EP-104IAR), Eupraxia is currently developing an extended-release post-surgical anesthetic (EP-105) and antibiotic (EP-201). Eupraxia hopes to add 1-2 additional candidates to our pipeline within the next year, including an internally ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
We are also developing antibodies that specifically target nfP2X7 for use in both solid and haematological tumours. Our preclinical data is very promising and studies show an excellent safety profile. By exploiting the modular nature of the antibody structure, the same panel of antibody sequences can be used to generate a variety of therapeutic antibody formats including, but not limited to, ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
BridgeBio is developing SHP2 inhibitors as potentially effective additions to the therapeutic arsenal for difficult-to-treat cancers. SHP2, encoded by the PTPN11 gene, links growth factor signaling with the downstream RAS/ERK/MAPK pathway to regulate cell growth and division. Over-activity of this pathway, often driven by distinct gene mutations, causes or contributes to many human cancers. ...
by:Numares GROUP Corp based inRegensburg, GERMANY
Cancer is among the leading causes of death worldwide. Approximately 38 % of men and women will be diagnosed with cancer at some point during their lifetimes (based on 2013 – 2015 data1). Cancer can occur in any organ and in any cell type and the variability in clinical presentation makes early diagnosis difficult. Common cancers with established benefit of early diagnosis but for ...
Manufactured by:AllCells based inAlameda, CALIFORNIA (USA)
Leukopaks are enriched leukapheresis products collected from healthy and consenting donors using the Spectra Optia® Apheresis System following an IRB-approved protocol. Leukopaks typically contain up to 50% T cells, 20% monocytes, 10% B cells, 10% NK cells, 3% granulocytes, and 3% hematocrit. Leukapheresis results in high yields of single-donor mononuclear cells (MNCs) compared to ...